14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
ABVC vs ASTI: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ABVC Captures Overall Composite Edge (47.4 HOLD vs 44.5 HOLD), While ASTI Leads 3–2 on Growth & Valuation Pillars
ABVC Overall Winner
6-Pillar Tally: ABVC 2 – 3 ASTI (1 Tie)
Matrix Metrics: ABVC 6 – 3 ASTI
As of Nov 20, 2026, ABVC BioPharma, Inc. (ABVC) captures the overall head-to-head institutional edge over Ascent Solar Technologies, Inc. (ASTI) on higher Unified Composite conviction (47.4/100 HOLD vs. 44.5/100 HOLD) after splitting the core matrix 6–3 (led by Growth & Scale, Profitability & Quality), while ASTI wins 3–2 across the 6-pillar growth and valuation breakdown. ABVC trades at $0.87 (N/M Forward P/E, 0.0% operating margin) versus ASTI at $0.77 (14.4x Forward P/E, -2759.6% operating margin).
Growth vs. Quality Trade-Off: ABVC earns the overall head-to-head edge with a stronger Unified Composite Score (47.4/100 HOLD vs. ASTI 44.5/100 HOLD) and 1.24β · 44% Vol risk profile, whereas ASTI leads top-line expansion (+514.3% YoY revenue growth, 0.96x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: ABVC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 35.2); meanwhile ASTI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 20.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABVC vs ASTI. Trailing 12-month operating profitability (ABVC 0.0% vs ASTI -2759.6%) and valuation multiples (ABVC N/M vs ASTI 14.4x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $23.9M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
ASTI Moat ProfileCyclical / Execution-Driven Positioning
Solar Operator
Competes within the Solar value chain with $12.6M market capitalization and -2759.6% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ABVC vs ASTI Key Questions & Quantitative Answers
As of Nov 20, 2026, ABVC BioPharma, Inc. (ABVC) captures the overall head-to-head institutional edge over Ascent Solar Technologies, Inc. (ASTI) on higher Unified Composite conviction (47.4/100 HOLD vs. 44.5/100 HOLD) after splitting the core matrix 6–3 (led by Growth & Scale, Profitability & Quality), while ASTI wins 3–2 across the 6-pillar growth and valuation breakdown. ABVC trades at $0.87 (N/M Forward P/E, 0.0% operating margin) versus ASTI at $0.77 (14.4x Forward P/E, -2759.6% operating margin). Growth vs. Quality Trade-Off: ABVC earns the overall head-to-head edge with a stronger Unified Composite Score (47.4/100 HOLD vs. ASTI 44.5/100 HOLD) and 1.24β · 44% Vol risk profile, whereas ASTI leads top-line expansion (+514.3% YoY revenue growth, 0.96x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ABVC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 35.2); meanwhile ASTI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 20.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ABVC leads the Growth & Scale pillar: ABVC posts +104.5% YoY revenue growth and +0.0% YoY earnings growth on $797,916 TTM revenue (100.0% gross margin, 0.0% operating margin), compared with ASTI at +514.3% YoY revenue growth and -90.2% YoY earnings growth on $338,161 TTM revenue (N/A gross margin, -2759.6% operating margin). On trailing 12-month operating scale, ABVC generates $797,916 in USD-normalized revenue versus $338,161 for ASTI. In operating R&D and SG&A reinvestment, ABVC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ASTI.
ASTI screens cheaper on headline valuation multiples. ABVC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 29.9x EV/Revenue (unreported EBITDA margin), whereas ASTI trades at 14.4x Forward P/E, 14.4x Trailing P/E, 0.96x PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABVC (-52.7% ROE) versus ASTI (-111.3% ROE) capital efficiency.
In options market volatility and institutional positioning, ABVC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.24β · 44% Vol realized risk). By comparison, ASTI carries 104.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.37β · 123% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.